The Triglyceride/Glucose Index and SGLT-2 Inhibitors
Study Details
Study Description
Brief Summary
This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and Research Hospital.
Methods: The data of the patients who were followed up for at least 3 months by making a retrospective file review will be recorded and analyzed. It is planned to start the study following the ethics committee's approval.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Purpose: This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and Research Hospital.
Methods: The data of the patients who were followed up for at least 3 months by making a retrospective file review will be recorded and analyzed. It is planned to start the study following the ethics committee's approval.
The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria stated below, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 injection and the trig/glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients. Triglyceride, glucose, and glycosylated hemoglobin values were checked at the beginning of the treatment and at the 3rd-month follow-up.
Inclusion Criteria:
Being diagnosed with type 2 DM be over 18 years old Using an SGLT-2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg or 25 mg) To be followed in our hospital for at least 3 months
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Type 2 diabetic patients using SGLT-2 inhibitors The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 treatment and the triglyceride glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients. |
Other: SGLT-2 inhibitors
This study is an observational study. It is not planned to do an interventional activity.
|
Outcome Measures
Primary Outcome Measures
- Change in triglyceride index [3 months]
Decreased triglyceride index among patients using SGLT-2 inhibitors.
Eligibility Criteria
Criteria
Inclusion Criteria:
Being diagnosed with type 2 DM be over 18 years old Using an SGLT-2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg or 25 mg) To be followed in our hospital for at least 3 months
Exclusion Criteria:
Having type 1 diabetes or gestational diabetes be under the age of 18 Being followed up in our hospital for less than 3 months Lack of triglyceride, glucose, and glycosylated hemoglobin values at the beginning of the treatment and at the 3rd month of control Patient receiving medical treatment with a diagnosis of dyslipidemia Being diagnosed with hypothyroidism Initiation of additional antidiabetic drugs other than SGLT 2 inhibitor in the same period
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Samsun Education and Research Hospital | Samsun | İlkadım | Turkey | 55200 |
Sponsors and Collaborators
- Samsun Education and Research Hospital
Investigators
- Principal Investigator: DÜRİYE SILA KARAGÖZ ÖZEN, Samsun Education and Research Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1